1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. North Carolina >
  6. Jazz Pharmaceuticals Acquires Chimerix

M&A Deal Summary

Jazz Pharmaceuticals Acquires Chimerix

On March 5, 2025, Jazz Pharmaceuticals acquired life science company Chimerix for 935M USD

Acquisition Highlights
  • This is Jazz Pharmaceuticals’ 7th transaction in the Life Science sector.
  • This is Jazz Pharmaceuticals’ 4th largest (disclosed) transaction.
  • This is Jazz Pharmaceuticals’ 5th transaction in the United States.
  • This is Jazz Pharmaceuticals’ 1st transaction in North Carolina.

M&A Deal Summary
Date 2025-03-05
Target Chimerix
Sector Life Science
Buyer(s) Jazz Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 935M USD
Advisor(s) Centerview Partners (Financial)
Skadden, Arps, Slate, Meagher & Flom
Cooley (Legal)

Target

Chimerix

Durham, North Carolina, United States
Chimerix is a drug development company that owns proprietary lipid prodrug technology to improve the efficacy of antiviral drugs. The Company’s lead compound, CMX001, is an active agent against a number of DNA viruses including smallpox and papilloma. Chimerix is also developing programs in CMV and HIV and is pursuing commercial opportunities to broaden the use of its technology. Chimerix was founded in 2000 and is based in Durham, North Carolina.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Jazz Pharmaceuticals

Dublin, Ireland
Category Company
Founded 2003
Sector Life Science
Employees2,800
Revenue 4.1B USD (2024)
DESCRIPTION
Jazz Pharmaceuticals office in Palo Alto, California.
Jazz Pharmaceuticals office in Palo Alto, California.

Jazz Pharmaceuticals is a specialty biopharmaceutical company that identifies, develops, and commercializes products to address unmet medical needs in focused therapeutic areas. Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland.

DEAL STATS #
Overall 7 of 7
Sector: Life Science M&A 7 of 7
Type: Add-on Acquisition M&A Deals 7 of 7
State: North Carolina M&A 1 of 1
Country: United States M&A 5 of 5
Year: 2025 M&A 1 of 1
Size (of disclosed) 4 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-03-28 Jazz Pharmaceuticals - Sunosi

Dublin, Ireland

Jazz Pharmaceuticals' Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

Sell $53M
Mergr

Solution for

Product

Company

Legal